Health
Medical
Biopharmaceutical

Aptinyx

$4.29
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.23%) Today
+$0.01 (0.23%) Today

Why Robinhood?

You can buy or sell Aptinyx and other stocks, options, ETFs, and crypto commission-free!

About

Aptinyx Inc. Common Stock, also called Aptinyx, is a clinical stage biopharmaceutical company. Read More It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

Employees
63
Headquarters
Evanston, Illinois
Founded
2015
Market Cap
142.70M
Price-Earnings Ratio
Dividend Yield
Average Volume
222.31K
High Today
$4.37
Low Today
$4.29
Open Price
$4.30
Volume
62.20K
52 Week High
$32.25
52 Week Low
$3.70

Collections

Health
Medical
Biopharmaceutical
Pharmaceutical
2018 IPO
US
North America

News

Associated PressMar 22

Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases

This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. EVANSTON, Ill., March 22, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today anno...

73
Seeking AlphaMar 21

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q4 2018 Results - Earnings Call Transcript

Aptinyx Inc. (NASDAQ:APTX) Q4 2018 Results Conference Call March 21, 2019 8:00 AM ET Company Participants Nick Smith - Senior Director, Corporate Development Norbert Riedel - President and CEO Ashish Khanna - CFO and Chief Business Officer Andy Kidd - COO Conference Call Participants Gerard Smith - SVB Leerink Gary Nachman - BMO Capital Markets Sadia Rahman - Charles Duncan Jessica Fye - J.P. Morgan Operator Good morning and welcome to the Aptinyx Fourth Quarter and Year-End 2018 Financial Resul...

8
Seeking AlphaMar 21

Aptinyx reports Q4 results

Aptinyx (APTX) Q4 results: Revenues: $1M (-16.7%). Net Loss: ($14.1M) (-95.8%); Loss Per Share: ($0.42) (+69.1%); Quick Assets: $150.6M (+63.5%). The Company initiated Phase 2a study of NYX-783 in patients with PTSD, data expected in 1H 2020. Also, Aptinyx is nearing completion of Phase 1 study of NYX-458 in healthy volunteers with data expected in 1H 2019. Previously: Aptinyx beats by $0.08, misses on revenue (March 21)...

64

Earnings

-$0.50
-$0.47
-$0.45
-$0.42
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.50 per share
Actual
-$0.42 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.